Viravaxx: SARS-COV-2 Vaccine Candidate To Induce Sterilizing Immunity

Viravaxx’ SARS-CoV-2 blocking Antibody Test informs if a COVID-19 convalescent patient or vaccinated person has developed neutralizing antibodies which block the interaction of RBD with ACE2. Viravaxx used its proprietary SARS-CoV-2 blocking Antibody Test to analyze serum samples from patients who recovered from COVID-19. The findings helped to understand the requirements

Viravaxx’ SARS-CoV-2 blocking Antibody Test informs if a COVID-19 convalescent patient or vaccinated person has developed neutralizing antibodies which block the interaction of RBD with ACE2. Viravaxx used its proprietary SARS-CoV-2 blocking Antibody Test to analyze serum samples from patients who recovered from COVID-19. The findings helped to understand the requirements for a vaccine to induce “sterilizing immunity”. This is of utmost importance since a significant percentage of COVID-19 convalescent patients do not produce antibodies capable of completely blocking RBD binding to the receptor protein ACE2. Recently generated pre-clinical data suggest that Viravaxx’ vaccine candidate is able to induce sterilizing immunity also in those patients who develop RBD-ACE2 blocking antibodies with only suboptimal capacity.

Contact

Viravaxx AG
Dr. Helmut Brunar
+43 664 415 9511
info(at)viravaxx.com

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.